Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Eli Lilly and Company
  6. Summary
    LLY   US5324571083

ELI LILLY AND COMPANY

(LLY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
222.52(c) 220.7(c) 226(c) 233.54(c) 224.09(c) Last
17 231 372 4 618 467 4 934 884 5 598 166 5 618 187 Volume
+10.15% -0.82% +2.40% +3.34% -4.05% Change
More quotes
Financials (USD)
Sales 2021 27 273 M - -
Net income 2021 6 537 M - -
Net Debt 2021 11 042 M - -
P/E ratio 2021 30,8x
Yield 2021 1,49%
Sales 2022 27 840 M - -
Net income 2022 7 334 M - -
Net Debt 2022 9 418 M - -
P/E ratio 2022 27,2x
Yield 2022 1,64%
Capitalization 204 B 204 B -
EV / Sales 2021 7,87x
EV / Sales 2022 7,66x
Nbr of Employees 35 000
Free-Float 99,8%
More Financials
Company
Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products... 
Read more
Sector
Pharmaceuticals
Calendar
08/03Earnings Release
More about the company
Ratings of Eli Lilly and Company
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about ELI LILLY AND COMPANY
06/11ELI LILLY AND  : Significant Insider Selling in Shares of Eli Lilly (LLY) Contin..
MT
06/11INSIDER TRENDS : Insider Sales Continue 90-Day Trend at Eli Lilly
MT
06/11ELI LILLY AND  : Thinking about trading options or stock in Crispr Therapeutics,..
PR
06/11MARKET CHATTER : Eli Lilly Says Internal Inquiry Shows No Wrongdoings in Stateme..
MT
06/10INSIDER TRENDS : Insider Prolongs Selling Trend at Eli Lilly
MT
06/10MARKET CHATTER : Eli Lilly Reportedly Says Internal Inquiry Shows Company Did No..
MT
06/10STREET COLOR : Eli Lilly Memo States Company Did Not Make False Statements to FD..
MT
06/10ALX ONCOLOGY  : to Collaborate With Lilly on Combination Therapy for Gastric Can..
MT
06/10ALX Oncology, Eli Lilly to Evaluate Gastric Cancer Treatment
DJ
06/09ELI LILLY AND  : Insider Selling in Eli Lilly (LLY) Shares Continues
MT
06/08INSIDER TRENDS : Insider Prolongs 90-Day Selling Trend at Eli Lilly
MT
06/07U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big..
RE
06/07US Stocks Mixed Monday as Dow Slips, Nasdaq Rises
MT
06/07CLOSE UPDATE : US Stocks Start Week Mostly Lower as Investors Continue to Weigh ..
MT
06/07ELI LILLY AND  : Lilly Shares Jump 12% Following FDA Approval of Biogen, Esai Al..
MT
More news
News in other languages on ELI LILLY AND COMPANY
06/07MÄRKTE USA/Wall Street startet uneinheitlich in die Woche
06/07Biogen s'envole après le feu vert de la FDA à son traitement contre la maladi..
06/07AKTIEN IM FOKUS : Alzheimermittel hilft Biogen auf Rekordhoch - Morphosys fest
06/03USA  : Dem al lavoro su disegno legge per ridurre prezzi farmaci
05/27FDA aprueba tratamiento de Covid-19 de Vir y GlaxoSmithKline en EEUU
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Analysis
U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day" for patients
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 217,94 $
Last Close Price 224,09 $
Spread / Highest target 13,3%
Spread / Average Target -2,74%
Spread / Lowest Target -21,9%
EPS Revisions
Managers and Directors
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY32.72%203 704
JOHNSON & JOHNSON4.82%434 405
ROCHE HOLDING AG10.68%328 612
PFIZER, INC.9.07%224 747
NOVARTIS AG-0.39%208 035
ABBVIE INC.7.72%203 857